ArticleScientific reports2025
Early arterial lactate trajectories and mortality risk in critically ill heart failure: a two-cohort trajectory analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactate is widely used as a biomarker of tissue hypoperfusion and illness severity in critically ill patients with heart failure (HF). While static lactate levels have prognostic value, dynamic changes in lactate over time may offer deeper insights into metabolic stress and clinical outcomes. However, the prognostic utility of lactate trajectories remains poorly defined in HF populations. We conducted a retrospective cohort study using the MIMIC-IV (n = 5,261) and MIMIC-III (n = 906) databases to identify distinct early arterial lactate trajectories in ICU-admitted HF patients. Latent class mixed model were used to categorize 72-hour lactate patterns, and association with in-hospital, 28-day, and 1-year mortality were assessed using multivariable logistic and Cox regression models. External validation was performed in the MIMIC-III cohort. Three distinct lactate trajectory classes were identified: low-stable (Class 1, 86.4%), early rise with delayed decline (Class 2, 4.1%), and early decline followed by re-elevation (Class 3, 9.6%). Compared with Class 1, Class 2 had higher in-hospital mortality (OR 6.88, 95% CI 4.86-9.74), 28-day mortality (HR 3.88, 95% CI 3.17-4.75), and 1-year mortality (HR 3.16, 95% CI 2.65-3.78; all P < 0.001). Class 3 also showed higher risks versus Class 1 (OR 3.03, 95% CI 2.32-3.98; 28-day HR 2.20, 95% CI 1.83-2.66; 1-year HR 1.83, 95% CI 1.56-2.15; all P < 0.001). Risks showed a consistent gradient (Class 2 > Class 3 > Class 1) across cohorts. Findings were consistent in the validation cohort. Sensitivity and subgroup analyses confirmed the robustness of these associations. Early arterial lactate trajectories were independently associated with both mortality in critically ill patients with HF. Trajectory-based profiling provides more nuanced prognostic insight than initial lactate values alone and may inform early risk stratification and ICU decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.